Yuly A. Remolina-Bonilla, MD

home / authors / yuly-remolina-bonilla-md

Articles

Erdafitinib in the Treatment of Metastatic Urothelial Carcinoma

Francisco J. Castro-Alonso, MD;Evelyn Beas-Lozano, MD;Yuly A. Remolina-Bonilla, MD;Thomas W. Flaig, MD;María T. Bourlon, MD, MSc, FASCO

June 23rd 2023

Francisco Castro-Alonso, MD, and colleagues describe the effects of the use of erdafitinib in a patient with metastatic urothelial bladder cancer.

Sjögren Syndrome Induced by Immune Checkpoint Inhibitors in a Patient with Advanced Renal Cell Carcinoma

Emilio Conde-Flores, MD;Yuly A. Remolina-Bonilla, MD;Francisco J. Castro-Alonso, MD;Nayeli A. Martínez-Ibarra, MS;Gabriela Hernández-Molina, MD;Mónica Chapa-Ibargüengoitia, MD;Armando Gamboa-Domínguez, MD;María T. Bourlon, MD, MSc, FASCO

August 14th 2021

This clinical quandary details a Mexican man, aged 77 years, who presented to the oncology clinic with a sternal mass. Based on the results, the patient fulfilled the 2016 American College of Rheumatology/European League Against Rheumatism classification criteria for Sjögren syndrome, thus the diagnosis triggered by immune checkpoint inhibitors was definitively established.

Challenges of Treating a Patient With Advanced Prostate Cancer During the COVID-19 Pandemic

Lucia Carril-Ajuria, MD;Yuly A. Remolina-Bonilla, MD;Alberto Carretero-Gonzalez, MD;Maricruz Martin-Soberon, MD;Daniel Castellano, MD;Christianne Bourlon, MD, MHSc;Guillermo de Velasco, MD, PhD;María T. Bourlon, MD, MSc, FASCO

August 12th 2020

Immune-Related Adverse Events Involving Multiple Organ Sites in a Patient Treated With Nivolumab Plus Ipilimumab

Yuly A. Remolina-Bonilla, MD;Brenda Jimenez-Franco, MD;María T. Bourlon, MD, MSc, FASCO;Elaine T. Lam, MD

May 13th 2020

Experts discuss the case of a 56-year-old white man who presents with multiple immune-related adverse events

What Are Treatment Options After Progression in PDL-1–Positive Metastatic Lung Adenocarcinoma after Chemo/IO?

Yuly A. Remolina-Bonilla, MD;Raul R. Trejo-Rosales, MD;Bruno Saldivar-Oviedo;Alejandro Gabutti, MD;María T. Bourlon, MD, MSc, FASCO

August 23rd 2019

What is the best treatment option after progression to chemotherapy/immunotherapy (chemo/IO) as first-line treatment for PD-L1–positive lung adenocarcinoma with no sensitizing mutations?